The mission of the Bioinformatics Shared Resource (BIC) is to provide Mayo Clinic Cancer Center (MCCC) members access to cutting-edge bioinformatics services and research collaborations through a highly experienced team of bioinformaticians. There are 4 categories of service lines offered by the BIC: 1) preprocessing of `omics' data using a suite of cutting-edge workflows; 2) exhaustive annotation services critical to the first-level interpretation of variants; 3) interpretation services (or tertiary analysis) involving pathway analysis; and 4) data-access services that provide centrally managed avenues to external data sources resources such as TCGA, GEO, and GTEX and to internal datasets (Mayo Clinic Biobank, Mayo Genomic Consortium), and genomics data-management solutions for large genomics projects. The BIC has made significant investments in developing the infrastructure to preprocess and interpret genomics data. With the help of Research IT, the bioinformatics technical team has implemented a comprehensive suite of workflows designed by and for faculty. This infrastructure is kept up to date by reviewing and integrating ?best of breed? open-source applications. When a workflow solution is not readily implementable from open-source applications, the BIC engage faculty in the design of novel methods. In addition to preprocessing workflows, applications have been developed to prioritize and filter variants and to visualize variants in the context of biological pathways, complementing a set of licensed commercial applications. Most importantly, the BIC has positioned itself as a bioinformatics research collaborator with MCCC members. BIC has representation at all 3 MCCC sites: Mayo Clinic in Rochester, MN (MCR); Mayo Clinic in Arizona (MCA); and Mayo Clinic in Florida (MCF). Over the last 5 years, BIC has supported more than 1240 projects for 176 MCCC members. During this period, BIC faculty were listed as key personnel on more than 60 submitted grants. Finally, BIC faculty and technical staff were co-authors of over 347 publications with MCCC members. BIC faculty are engaged in the Women's Cancer, Hematologic Malignancies and Gastrointestinal Cancer Programs and their associated Breast, Ovarian, Lymphoma, Multiple Myeloma, and Pancreatic SPOREs. The BIC has established close partnerships with the Genome Analysis Shared Resource and Biostatistics Shared Resource to provide effective and seamless support to MCCC members. The BIC has also partnered with the institution's Research IT resource to establish and maintain the infrastructure needs to manage genomics data and design optimized workflows.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096

Showing the most recent 10 out of 1129 publications